Results to be Featured in Oral Late Breaker
Presentation
SAN
DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that results from the company's Phase 2b clinical trial of VK2809, the company's novel
liver-selective thyroid hormone receptor beta agonist, in patients
with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also
referred to as metabolic dysfunction associated steatohepatitis,
MASH) will be highlighted in an oral late breaker presentation at
the 75th Liver Meeting® 2024, the annual
meeting of the American Association for the Study of Liver Disease
(AASLD). The Liver Meeting 2024 is being held November 15-19, 2024, in San Diego, California.
Details of the oral presentation are as follows:
Title: Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with
Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A
Randomized, Placebo-Controlled Trial
Presenting Author: Rohit Loomba, M.D., MHSc,
Director, NAFLD Research Center and Professor of Medicine,
University of California, San Diego
Session: Late Breaking Abstract Parallel Session
3
Date/Time: Tuesday, November 19, 2024, 11:00 –
11:10 a.m. Pacific Time
Location: San Diego Convention Center
About VK2809
VK2809 is an orally available, tissue and receptor-subtype
selective agonist of the thyroid hormone beta receptor (TRβ) that
possesses selectivity for liver tissue, as well as the beta
receptor subtype, suggesting promising therapeutic potential in a
range of lipid disorders. The Phase 2b VOYAGE study of VK2809 in patients with
biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred
to as metabolic dysfunction associated steatohepatitis, MASH) and
fibrosis successfully achieved both the trial's primary and
secondary endpoints. VK2809 also successfully achieved primary and
secondary endpoints in a Phase 2a study for the treatment of
patients with elevated LDL-C and non-alcoholic fatty liver disease
(NAFLD). Selective activation of the thyroid hormone beta receptor
in liver tissue is believed to favorably affect cholesterol and
lipoprotein levels via multiple mechanisms, including increasing
the expression of genes associated with lipid metabolism and
clearance.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 and a Phase 2 trial evaluating
VK2735 (dosed subcutaneously) for metabolic disorders demonstrated
an encouraging safety and tolerability profile as well as positive
signs of clinical benefit. Concurrently, the company is evaluating
an oral formulation of VK2735 in a Phase 1 trial. Viking is also
developing VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders. The compound successfully
achieved both the primary and secondary endpoints in a recently
completed Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred
to as metabolic dysfunction associated steatohepatitis, MASH) and
fibrosis. In a Phase 2a trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company's newest program is
evaluating a series of internally developed dual amylin and
calcitonin receptor agonists (or DACRAs) for the treatment of
obesity and other metabolic disorders. In the rare disease
space, Viking is developing VK0214, a novel, orally available,
small molecule selective thyroid hormone receptor beta agonist for
the potential treatment of X-linked adrenoleukodystrophy
(X-ALD). In a Phase 1b clinical trial in patients
with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was
shown to be safe and well-tolerated, while driving significant
reductions in plasma levels of very long-chain fatty acids (VLCFAs)
and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-data-from-phase-2b-voyage-study-of-vk2809-in-patients-with-biopsy-confirmed-nashmash-at-the-75th-liver-meeting-2024-302302102.html
SOURCE Viking Therapeutics, Inc.
